Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873874 | 0.83 | NPC1 (0.71) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL973109 | 0.82 | NPC1 (0.64) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL1428784 | 0.81 | AKT1 (0.60) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL18221717 | 0.80 | NPC1 (0.63) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL28669282 | 0.80 | KDM4E (0.58) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL15825411 | 0.80 | ALDH1A1 (0.62) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL25790023 | 0.79 | KDM4E (0.57) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL1429286 | 0.78 | ALDH1A1 (0.67) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL1428788 | 0.78 | AKT1 (0.50) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL8874527 | 0.77 | PTGS2 (0.57) | NPC1RAB9AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658857-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-19 | — | — | US | claimed |
| EP-0683779-A1 | IMIDAZOAZINES | BAYER AG (DE) | 1995-11-29 | — | — | EP | claimed |
| WO-1994018198-A1 | IMIDAZOAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-18 | — | — | WO | claimed |
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2062893-A1 | Fused imidazoles for cancer treatment | Bayer Schering Pharma AG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| US-5658857-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-19 | — | — | US | disclosed |
| EP-0683779-A1 | IMIDAZOAZINES | BAYER AG (DE) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018198-A1 | IMIDAZOAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | NPC1 1448/4885RAB9A 457/4885ALDH1A1 3757/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | NPC1 1448/4885RAB9A 457/4885ALDH1A1 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.